Literature DB >> 17005467

Somatic stem cells and the origin of cancer.

José A Martínez-Climent1, Enrique J Andreu, Felipe Prosper.   

Abstract

Most human cancers derive from a single cell targeted by genetic and epigenetic alterations that initiate malignant transformation. Progressively, these early cancer cells give rise to different generations of daughter cells that accumulate additional mutations, acting in concert to drive the full neoplastic phenotype. As we have currently deciphered many of the gene pathways disrupted in cancer, our knowledge about the nature of the normal cells susceptible to transformation upon mutation has remained more elusive. Adult stem cells are those that show long-term replicative potential, together with the capacities of self-renewal and multi-lineage differentiation. These stem cell properties are tightly regulated in normal development, yet their alteration may be a critical issue for tumorigenesis. This concept has arisen from the striking degree of similarity noted between somatic stem cells and cancer cells, including the fundamental abilities to self-renew and differentiate. Given these shared attributes, it has been proposed that cancers are caused by transforming mutations occurring in tissue-specific stem cells. This hypothesis has been functionally supported by the observation that among all cancer cells within a particular tumor, only a minute cell fraction has the exclusive potential to regenerate the entire tumor cell population; these cells with stem-like properties have been termed cancer stem cells. Cancer stem cells can originate from mutation in normal somatic stem cells that deregulate their physiological programs. Alternatively, mutations may target more committed progenitor cells or even mature cells, which become reprogrammed to acquire stem-like functions. In any case, mutated genes should promote expansion of stem/progenitor cells, thus increasing their predisposition to cancer development by expanding self-renewal and pluripotency over their normal tendency towards relative quiescency and proper differentiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005467     DOI: 10.1007/s12094-006-0035-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  231 in total

1.  Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex.

Authors:  Thomas Kramps; Oliver Peter; Erich Brunner; Denise Nellen; Barbara Froesch; Sandipan Chatterjee; Maximilien Murone; Stephanie Züllig; Konrad Basler
Journal:  Cell       Date:  2002-04-05       Impact factor: 41.582

2.  p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis.

Authors:  L Chin; S E Artandi; Q Shen; A Tam; S L Lee; G J Gottlieb; C W Greider; R A DePinho
Journal:  Cell       Date:  1999-05-14       Impact factor: 41.582

Review 3.  The Hedgehog and Wnt signalling pathways in cancer.

Authors:  J Taipale; P A Beachy
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

4.  A microRNA cluster as a target of genomic amplification in malignant lymphoma.

Authors:  H Tagawa; M Seto
Journal:  Leukemia       Date:  2005-11       Impact factor: 11.528

5.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

6.  Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster.

Authors:  Emmanuel Caussinus; Cayetano Gonzalez
Journal:  Nat Genet       Date:  2005-09-04       Impact factor: 38.330

7.  Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation.

Authors:  G Bhardwaj; B Murdoch; D Wu; D P Baker; K P Williams; K Chadwick; L E Ling; F N Karanu; M Bhatia
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

8.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Authors:  Ryan T Phan; Riccardo Dalla-Favera
Journal:  Nature       Date:  2004-12-02       Impact factor: 49.962

9.  Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation.

Authors:  Chainarong Tunyaplin; A L Shaffer; Cristina D Angelin-Duclos; Xin Yu; Louis M Staudt; Kathryn L Calame
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

10.  Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program.

Authors:  Yongping G Crawford; Mona L Gauthier; Anita Joubel; Kristin Mantei; Krystyna Kozakiewicz; Cynthia A Afshari; Thea D Tlsty
Journal:  Cancer Cell       Date:  2004-03       Impact factor: 31.743

View more
  21 in total

Review 1.  Cancer stem cells: progress and challenges in lung cancer.

Authors:  Amanda K Templeton; Shinya Miyamoto; Anish Babu; Anupama Munshi; Rajagopal Ramesh
Journal:  Stem Cell Investig       Date:  2014-04-15

Review 2.  Lung cancer stem cells-characteristics, phenotype.

Authors:  Georgia Hardavella; Rachel George; Tariq Sethi
Journal:  Transl Lung Cancer Res       Date:  2016-06

3.  Anti-human embryonic stem cell monoclonal antibody Hesca-2 binds to a glycan epitope commonly found on carcinomas.

Authors:  Mohamed G Shoreibah; Crystal L Jackson; Paul W Price; Richard Meagher; Andrew K Godwin; Qi Cai; Jeffrey C Gildersleeve
Journal:  Stem Cells Dev       Date:  2010-11-08       Impact factor: 3.272

4.  A stem cell niche dominance theorem.

Authors:  Olaf Wolkenhauer; Darryl K Shibata; Mihajlo D Mesarović
Journal:  BMC Syst Biol       Date:  2011-01-08

5.  miR-145-mediated suppression of cell growth, invasion and metastasis.

Authors:  Mohit Sachdeva; Yin-Yuan Mo
Journal:  Am J Transl Res       Date:  2010-03-25       Impact factor: 4.060

6.  Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.

Authors:  David R Emlet; Puja Gupta; Marina Holgado-Madruga; Catherine A Del Vecchio; Siddhartha S Mitra; Shuang-Yin Han; Gordon Li; Kristin C Jensen; Hannes Vogel; Linda Wei Xu; Stephen S Skirboll; Albert J Wong
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

Review 7.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

Review 8.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy.

Authors:  Madhuri Kakarala; Max S Wicha
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

9.  Competing views on cancer.

Authors:  Carlos Sonnenschein; Ana M Soto; Annapoorni Rangarajan; Prakash Kulkarni
Journal:  J Biosci       Date:  2014-04       Impact factor: 1.826

Review 10.  Regenerative medicine and injection therapies in stress urinary incontinence.

Authors:  Christopher J Hillary; Sabiniano Roman; Sheila MacNeil; Wilhelm K Aicher; Arnulf Stenzl; Christopher R Chapple
Journal:  Nat Rev Urol       Date:  2020-01-23       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.